Key Updates
British American Tobacco has declined -2.50% since the last report to £4,244, with YTD gains contracting sharply to +0.71% from the previous +3.30%. The accelerating downward trajectory reflects mounting regulatory and reputational pressures from Formula 1 sponsorship controversies, which have now drawn criticism from over 160 health organizations. The 5-day decline of -8.10% and 1-month decline of -7.92% signal intensifying negative sentiment, despite the company's strong 2025 financial results reported in February. The stock has surrendered most of its early-year gains, with momentum clearly shifting bearish across all short-term timeframes.
Current Trend
BAT shares are in a clear downtrend across all short-term periods, with the 1-day (-0.89%), 5-day (-8.10%), and 1-month (-7.92%) performance all negative. The YTD gain of +0.71% represents a significant deterioration from the +5.93% reported two reports ago and +8.33% three reports ago, indicating systematic erosion of early-year gains. The 6-month performance of +2.69% suggests medium-term support exists, but recent momentum is decisively bearish. The stock has now declined -7.61% from the £4,565 level reported on March 3rd, representing a substantial correction in just six trading days.
Investment Thesis
The investment thesis centers on BAT's strategic transformation from combustible tobacco to reduced-risk products, supported by strong financial execution and market share gains in next-generation categories. The company delivered robust 2025 results with pretax profit surging to £9.86 billion from £3.54 billion, while new categories revenue grew 7% to £3.62 billion. BAT's Velo nicotine pouch brand is gaining U.S. market share against Philip Morris' Zyn through higher nicotine strengths and promotional strategies. The company maintains dividend growth with a 2% increase to 245.04 pence per share, supporting income-focused investors. However, the thesis faces headwinds from regulatory challenges in key markets, reputational risks from youth-focused marketing controversies, and operational difficulties including the South African factory closure due to 75% illicit market penetration and ongoing U.S. litigation over North Korea sanctions breaches.
Thesis Status
The investment thesis is under pressure as reputational and regulatory risks intensify, offsetting strong financial performance. While operational execution remains solid—evidenced by profit growth and market share gains in nicotine pouches—the mounting Formula 1 sponsorship controversy poses significant downside risks. The criticism from 162 health organizations and involvement of major youth-oriented F1 partners (Disney, Lego, Mattel) could force sponsorship termination, undermining BAT's marketing strategy for reduced-risk products. The shareholder lawsuit over North Korea sanctions disclosure failures adds legal uncertainty, while the South African factory closure highlights vulnerability to illicit trade in emerging markets. The ITC investigation into illegal vapes, though potentially beneficial long-term, creates near-term uncertainty with no expected impact before 2027. The thesis remains intact from a fundamental standpoint but faces elevated execution and regulatory risks that are currently dominating price action.
Key Drivers
The primary driver of recent weakness is the escalating Formula 1 sponsorship controversy, with over 160 organizations calling for termination of BAT's McLaren partnership promoting Velo nicotine pouches. The controversy is amplified by F1's partnerships with Disney, Lego, and Mattel, creating reputational conflicts as health groups argue tobacco companies target F1's 4 million child viewers aged 8-12. Legal risks are compounding with over 100 shareholders filing suit over alleged failures to disclose North Korea sanctions breaches that resulted in $635 million in U.S. penalties in 2023. Operationally, BAT is closing its South African factory due to illicit cigarettes comprising 75% of the market. The ITC investigation into illegal vapes following BAT's complaint could reduce the unauthorized market by one-third, though benefits won't materialize until 2027.
Technical Analysis
BAT has broken below key support levels established in early March, with the current £4,244 price representing a -7.61% decline from the £4,565 level on March 3rd. The accelerating downward momentum is evident in the progressively steeper declines: -2.08% initially, then -2.21%, -2.49%, and now -2.50% between reports. The 5-day decline of -8.10% signals capitulation selling, while the 1-month decline of -7.92% confirms a established downtrend. The YTD performance has deteriorated from +10.63% to +0.71% in just six days, indicating systematic unwinding of long positions. The 6-month gain of +2.69% suggests potential support exists around the £4,130-£4,150 level (approximately 2.5% below current price), but near-term momentum remains decisively negative with no clear stabilization signals.
Bull Case
- Exceptional profit growth trajectory: Pretax profit surged to £9.86 billion in 2025 from £3.54 billion in 2024, with adjusted operating profit reaching £11.89 billion versus consensus of £11.29 billion, demonstrating superior operational execution. Source: WSJ
- Next-generation products gaining market share: Velo nicotine pouches are capturing U.S. market share from Philip Morris' Zyn and Altria's On! through higher nicotine strengths and promotional strategies, with new categories revenue growing 7% to £3.62 billion. Source: Reuters
- Potential 33% reduction in illegal vape competition: ITC investigation could eliminate one-third of the unauthorized vape market that currently comprises 70% of U.S. e-cigarette sales, benefiting BAT's compliant Vuse brand once implemented. Source: Reuters
- Consistent dividend growth supporting valuation floor: Board declared 245.04 pence per share dividend, representing 2% year-on-year increase, maintaining BAT's appeal to income-focused investors and providing downside support. Source: Morningstar
- Experienced leadership continuity during transformation: Board extended Chair Luc Jobin's tenure for up to two additional years, providing stability as the company navigates its strategic shift to reduced-risk products. Source: WSJ
Bear Case
- Major reputational crisis from F1 youth marketing controversy: Over 160 health organizations demanding termination of McLaren sponsorship, with Disney, Lego, and Mattel potentially pressured to force F1 action, threatening key marketing channel for reduced-risk products targeting 4 million child viewers. Source: PR Newswire
- Shareholder litigation over sanctions disclosure failures: Over 100 shareholders filed lawsuit regarding alleged inadequate disclosure of North Korea sanctions breaches that resulted in $635 million U.S. penalties, creating legal uncertainty and potential financial exposure. Source: Reuters
- South African factory closure signals emerging market vulnerability: Closing sole South African facility after 51 years due to 75% illicit market penetration demonstrates inability to compete against illegal trade in key markets, with similar risks in other jurisdictions. Source: Bloomberg
- Competitive pressure from Philip Morris' smoke-free momentum: Philip Morris achieving 41.5% revenue from reduced-risk products with target of two-thirds by 2030, demonstrating faster transformation pace than BAT and superior market positioning in next-generation categories. Source: Morningstar
- Delayed benefits from ITC vape enforcement action: Despite favorable ITC ruling, impact on illegal vape market unlikely before 2027 due to long supply chains and large inventories, meaning near-term pressure on Vuse continues from 70% unauthorized market share. Source: Reuters